Source: Eur Respir J 2007; 30: 409-410
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Borrill Z., Woodhead M., Soriano J. B., Barnes N. C.. Eppur si muove, or COPD treatment success and inflammation. Eur Respir J 2007; 30: 409-410

Member's Comments

No comment yet.

Related content which might interest you: Tt anti fibrotiques hors FPI: approche raisonnée / Anti-fibrotic treatments for conditions other than idiopathic pulmonary fibrosis Source: Virtual Congress 2020 – French programme 2020: Part I Year: 2020 Anti-interleukin-5 therapy in severe asthma}, Source: Eur Respir Rev 2013; 22: 251-257 Year: 2013 Targeting the IL-1β – IL-17A inflammatory axis for the treatment of viral-induced exacerbations of COPD Source: Annual Congress 2012 - Animal models of asthma and COPD and late-breaking abstracts on RCT in asthma and COPD Year: 2012 Thermoplastie bronchique : indications actuelles / Asthma thermoplasty: current indications Source: Virtual Congress 2021 – French programme 2021 Year: 2021 COPD: not just a respiratory disease! Source: Eur Respir J 2006; 28: Suppl. 50, 105s Year: 2006 LATE-BREAKING ABSTRACT: Stratification of patients with COPD by frequence of exacerbations is an essential step for what to treat in COPD. - A survey in a real life COPD population Source: Annual Congress 2013 –Predictors and triggers of asthma and COPD exacerbations Year: 2013 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbation and improves lung function versus salmeterol/fluticasone (SFC) in patients with and without prior ICS use: The FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 LATE-BREAKING ABSTRACT: Eosinophilic inflammation in COPD: During clinical stability and exacerbations. The AERIS study Source: International Congress 2015 – The relevance of diagnostic and monitoring tools in clinical practice Year: 2015 Implications of under treatment of stable COPD (SAVING study) Source: International Congress 2015 – New data on established treatments for COPD Year: 2015 Exacerbations and hospitalizations due to exacerbations in asthma-COPD overlap sindrome (ACOS) in PUMA study Source: International Congress 2016 – Asthma, COPD, and ACOS: physical activity, dietary aspects, and diseases burden Year: 2016 RT protocol reduces AECOPD readmissions Source: International Congress 2016 – In-patient and out-patient COPD management Year: 2016 Indacaterol/glycopyrronium (IND/GLY) is more effective than salmeterol/fluticasone (SFC) in reducing exacerbations, regardless of outcome measurement utilised: Results from the FLAME study Source: International Congress 2016 – Novel insights into the treatment of COPD Year: 2016 Indacaterol/glycopyrronium (IND/GLY) reduces exacerbations compared with salmeterol/fluticasone (SFC) in various sub-groups from the FLAME study Source: International Congress 2016 – Pharmacological treatment of COPD: focus on LABA/LAMA combinations Year: 2016 Mucoviscidose: enfin des traitements ciblés / Cystic fibrosis: targeted therapies, at last ! Source: Virtual Congress 2020 – French programme 2020: Part I Year: 2020 Severe refractory asthma: an update}, Source: Eur Respir Rev 2013; 22: 227-235 Year: 2013 Heliox administration in patients with COPD exacerbation – Technical aspects Source: Annual Congress 2010 - Mechanical ventilation and weaning Year: 2010